exp3174 has been researched along with transforming growth factor beta in 1 studies
| Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 236 | 29 | 43 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beaumont, J; Díez, J; Fortuño, A; González, A; López, B; Miguel-Carrasco, JL; Moreno, MU; Ravassa, S; San José, G; Zalba, G | 1 |
1 other study(ies) available for exp3174 and transforming growth factor beta
| Article | Year |
|---|---|
Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line; Connective Tissue Growth Factor; Fibrosis; Humans; Losartan; Male; Myocardium; Myofibroblasts; Protein-Lysine 6-Oxidase; Rats; Rats, Wistar; Transforming Growth Factor beta; Ventricular Dysfunction, Left | 2017 |